198 related articles for article (PubMed ID: 38017492)
1. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.
Busato D; Capolla S; Durigutto P; Mossenta M; Bozzer S; Sblattero D; Macor P; Dal Bo M; Toffoli G
J Transl Med; 2023 Nov; 21(1):864. PubMed ID: 38017492
[TBL] [Abstract][Full Text] [Related]
2. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
3. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
4. The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma.
Busato D; Mossenta M; Dal Bo M; Macor P; Toffoli G
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142190
[TBL] [Abstract][Full Text] [Related]
5. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
[TBL] [Abstract][Full Text] [Related]
6. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with
Watabe T; Kabayama K; Naka S; Yamamoto R; Kaneda K; Serada S; Ooe K; Toyoshima A; Wang Y; Haba H; Kurimoto K; Kobayashi T; Shimosegawa E; Tomiyama N; Fukase K; Naka T
J Nucl Med; 2023 Dec; 64(12):1949-1955. PubMed ID: 37827841
[TBL] [Abstract][Full Text] [Related]
8. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma.
Kayed H; Kleeff J; Keleg S; Jiang X; Penzel R; Giese T; Zentgraf H; Büchler MW; Korc M; Friess H
Int J Oncol; 2006 Nov; 29(5):1139-48. PubMed ID: 17016645
[TBL] [Abstract][Full Text] [Related]
9. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis.
Moutinho-Ribeiro P; Adem B; Batista I; Silva M; Silva S; Ruivo CF; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Lopes S; Vilas-Boas F; Durães C; Lopes J; Barroca H; Carneiro F; Melo SA; Macedo G
Dig Liver Dis; 2022 Jul; 54(7):871-877. PubMed ID: 34840127
[TBL] [Abstract][Full Text] [Related]
10. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
13. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
[TBL] [Abstract][Full Text] [Related]
14. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.
Frampton AE; Prado MM; López-Jiménez E; Fajardo-Puerta AB; Jawad ZAR; Lawton P; Giovannetti E; Habib NA; Castellano L; Stebbing J; Krell J; Jiao LR
Oncotarget; 2018 Apr; 9(27):19006-19013. PubMed ID: 29721179
[TBL] [Abstract][Full Text] [Related]
15.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
16. Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.
Moutinho-Ribeiro P; Batista IA; Quintas ST; Adem B; Silva M; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Medas R; Lopes S; Vilas-Boas F; Baptista M; Dias-Silva D; Esteves AL; Martins F; Lopes J; Barroca H; Carneiro F; Macedo G; Melo SA
World J Gastroenterol; 2022 Aug; 28(31):4310-4327. PubMed ID: 36159010
[TBL] [Abstract][Full Text] [Related]
17. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
18. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
[TBL] [Abstract][Full Text] [Related]
19. A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis.
Whipple CA; Young AL; Korc M
Oncogene; 2012 May; 31(20):2535-44. PubMed ID: 21996748
[TBL] [Abstract][Full Text] [Related]
20. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
